The National Surgical Adjuvant Breast and Bowel Project B35 and International Breast Cancer Intervention Studies II Ductal Carcinoma In Situ trials showed similar treatment effects of anastrozole and tamoxifen in reducing cancer recurrence risk among ductal carcinoma in situ (DCIS) patients. Studies have shown low levels of hormone therapy drug initiation for DCIS patients, but the current body of literature lacks information on the 5-year adherence rates for these drugs from population-based studies. METHODS: This study evaluated the initiation and 5-year adherence levels for women aged 66 to 85 years who had been diagnosed with estrogen receptor (ER)-positive DCIS between 2007 and 2011 according to the Surveillance, Epidemiology, and End Results and Texas Cancer Registry databases linked to Medicare claims. Chi-square tests, trend tests, and logistic regression were used to identify factors associated with treatment initiation. RESULTS: There were 2871 women with ER-positive DCIS, and approximately 45% began treatment with tamoxifen or aromatase inhibitors (AIs) within 1 year of their DCIS diagnosis. The median age was 73 years for the users and 75 years for the nonusers. Women aged 66 to 70 years who underwent lumpectomy and radiation therapy were significantly more likely to initiate hormone therapy. The initiation of therapy was also significantly associated with patients' geographic location, education, marital status, diagnosis year, and race/ethnicity. Among users, adherence decreased from 67% in the first year to 30% in the fifth year. CONCLUSIONS: Initiation and adherence levels for tamoxifen or AIs among older women with ER-positive DCIS are low. Future studies should develop methods to ensure that informed discussions take place between health care providers and patients regarding hormonal therapy for cancer prevention. Cancer 2017;123:940-7. V C 2016 American Cancer Society.
INTRODUCTION
Although breast ductal carcinoma in situ (DCIS) is noninvasive, women with DCIS are at higher risk of developing invasive breast cancer than women without it. 1 The standard treatment for DCIS is lumpectomy followed by radiation therapy (LRT). For estrogen receptor (ER)-positive tumors, the use of a hormone therapy agent such as tamoxifen for 5 years is also recommended to reduce the risk of second primary breast cancers. Tamoxifen was proven to reduce the risk of invasive breast cancer in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B24 trial and the United Kingdom, Australia, and New Zealand trial. [2] [3] [4] Aromatase inhibitors (AIs) are drugs that can block the synthesis of estrogen and inhibit ER-positive breast tumor growth among postmenopausal women. 5 Results from the NSABP B35 trial showed that the 10-year breast cancer event rate was 4% lower for patients who used anastrozole versus tamoxifen among postmenopausal women who were 60 years old or younger. 6 Results from the International Breast Cancer Intervention Studies II Ductal Carcinoma In Situ (IBIS-II DCIS) trial showed that anastrozole had a risk reduction effect similar to that of tamoxifen in DCIS patients. 7 AIs have been used off label to treat DCIS.
Although tamoxifen and AIs can markedly reduce the risk of invasive breast cancer, their use among ERpositive DCIS patients remains low. Nichols et al 8 reported a 41% initiation rate for tamoxifen or AIs among ER-positive DCIS patients on the basis of 727 Group Health Cooperative enrollees from 1996 to 2011. Virnig et al 9 reported a 43.9% initiation rate for these drugs among ER-positive DCIS patients diagnosed between 2006 and 2007 on the basis of Surveillance, Epidemiology, and End Results-Medicare data. The literature is devoid of population-based studies for determining the 5-year adherence rate among women who initiate treatment. Because the optimal preventive effect of these drugs requires 5 years of treatment, adherence is key for patients to obtain the maximum prevention benefit. The 5-year tamoxifen or AI completion rate among DCIS patients from the NSABP B35 and IBIS-II DCIS clinical trials was 64% and 67%, respectively. 6, 7 Factors that have been associated with nonadherence to tamoxifen use include a patient's age, adverse events due to tamoxifen or AIs, and physician recommendations, among others. 10 Currently, no population-based study exists that evaluates tamoxifen or AI adherence in older women with DCIS. It is important to evaluate adherence among older women to determine whether continued treatment, the current standard of care used to reduce the risk of DCIS progressing to invasive disease, is being appropriately given to this patient population. In this study, we used Medicare Part D data to evaluate tamoxifen or AI initiation and to discover the determinants that influence their use. We hypothesized that patients' demographic characteristics, tumor characteristics, primary treatment modality, and geographic region influence treatment initiation. We also assessed the 5-year adherence. We hypothesized that the 5-year adherence rate in this real-world population-based study would be lower than rates obtained from clinical trials.
MATERIALS AND METHODS
We used Surveillance, Epidemiology, and End ResultsMedicare and Texas Cancer Registry-Medicare linked data for this study. 11 We selected women who were 66 years old or older, had been diagnosed with ER-positive DCIS between January 2007 and December 2011, and had undergone mastectomy or lumpectomy. Patients had Medicare Parts A and B and were not covered by a health maintenance organization for 1 year before and 1 year after their diagnosis. Patients had a Medicare Part D prescription drug plan for at least 12 months after their diagnosis or until death if they died within 12 months. The initiation of use was evaluated from the DCIS diagnosis until 12 months after the diagnosis. We defined a patient's first treatment date as the first prescription drug date and the last treatment date as 1) the end of Medicare Part D continuous coverage, 2) the end of the study period (December 2012), 3) the date of the patient's secondary cancer diagnosis, 4) death, or 5) the end of the 5-year treatment (whichever event occurred first). Adherence was defined as the initiation of tamoxifen or AI use and persistence in completing the treatment from 1 to 5 years after the initiation of its use. We measured the adherence by computing the proportion of days covered (PDC) in treatment years 1 to 5 for women who initiated the treatment. Each year, a patient was considered to be adherent to treatment if she had a PDC 80%. In a treatment year, the adherence was calculated as the number of patients with a PDC 80% divided by the number of total eligible patients. Eligible patients were those who had full Medicare Part D coverage by the last treatment date in that year. We adjusted the days of drug supply for early refilled prescriptions by using the algorithm provided by Wang et al. 14 Differences in nominal categorical variables were analyzed with the chi-square test, and differences in ordered categorical variables between 2 groups were analyzed with the Cochrane-Armitage trend test. A binomial distribution was used to compute the confidence intervals for adherence rates. All tests were 2-sided, and a P value less than.05 was considered significant. A forward logistic regression selection approach was used to build the multivariable regression model. A variable was selected for the model with a P value .1. We conducted a sensitivity analysis in a multiple logistic regression by excluding mastectomy patients to determine whether predictors of hormonal therapy were different among women treated with mastectomy versus lumpectomy.
The data were analyzed with SAS 9.4 software, which was developed by the SAS Institute (Cary, NC). This study received an exemption from the institutional review boards at The University of Texas MD Anderson Cancer Center.
RESULTS
We identified 2871 women aged 66 to 85 years who were diagnosed with ER-positive DCIS from 2007 to 2011. The median age was 73.3 years. Tamoxifen or AI use was started by 1297 women (45.2%) within 1 year of their diagnosis. Approximately 72% of them used tamoxifen, 24% used an AI, and 4% switched between these 2 drugs. The median interval from the DCIS diagnosis to the first prescription was 3 months.
The distributions for patient age, education, treatment with surgery and radiation, and geographic location were significantly different between users and nonusers with a P value < .0001 (Table 1) . Users with a median age of 73 years were younger than nonusers with a median age of 75 years. Women who underwent LRT were most likely to initiate the treatment (54.6%), and they were followed by those treated with only lumpectomy (32.9%) or mastectomy (33.6%). Among the 13 cancer registries, use was lowest in Seattle (28.9%) and highest in Louisiana (59.2%; Fig. 1 ). Other variables such as race/ethnicity, marital status, and median household income level in the census tract of residence were significantly different between users and nonusers (P < .05). The initiation of tamoxifen or AIs was more common in Hispanic patients (55.6%) and black patients (51.6%) than white patients (44.1%; P 5 .0003).
In the multivariable analysis, the final model included the treatment modality, age, geographic region, education level, race/ethnicity, marital status, and year of diagnosis. Patients who were treated with lumpectomy (odds ratio, 0.48; 95% confidence interval, 0.39-0.60) or mastectomy (odds ratio, 0.40; 95% confidence interval, 0.33-0.49) were less likely to be users than LRT patients. Overall, patients were more likely to initiate drug use if they were younger than 71 years at diagnosis, were Hispanic, were married, lived in census tracts with low levels of education, underwent LRT, and were diagnosed before 2010 ( Table 2 ). The predictors of use in women undergoing lumpectomy were similar to those in Table 2 except that the diagnosis year was not significant (Supporting Table 4 [see online supporting information]).
The median Part D coverage for the 1297 users was 34 months (interquartile range, 19-48 months). The median days covered by prescribed drugs was 659 days (interquartile range, 300-1135 days). The adherence rate in the first treatment year was 67%; this decreased to approximately 50% in the second to fourth treatment years and further declined to 30% in the fifth year (Table 3 and Fig. 2 ).
DISCUSSION
In this study, we found that 45.2% of women with ERpositive DCIS began therapy with tamoxifen or AIs. Patients who were treated with lumpectomy or mastectomy without radiation, were 71 years old or older, lived in the western United States, lived in census tracts with high median levels of education, were white, were unmarried, and were diagnosed after 2009 were less likely to use tamoxifen or AIs. Among users, only 30% completed 5 years of treatment.
Low levels of tamoxifen or AI uptake and adherence may be attributable to treatment toxicities and the small benefit from hormone therapy after lumpectomy and radiation. Both tamoxifen use and AI use are associated with side effects. Approximately 29% of patients who receive tamoxifen or an AI experience grade 3 or higher toxicities. 6 These adverse events include difficulty with bladder control, gynecological symptoms, thrombosis or embolism, musculoskeletal pain, and vaginal symptoms. 15 In the IBIS-II DCIS trial, approximately 33% of the patients discontinued tamoxifen or anastrozole, with one of the main reasons being adverse events. 7 In addition to the toxicities, the benefit of using these drugs to prevent invasive breast cancer after LRT seems limited because of the already excellent prognosis for most of these women. The 10-year cumulative rate of invasive ipsilateral breast tumor recurrence after LRT is 10.6% versus 5.8% with the addition of 5 years of tamoxifen treatment. According to this, 21 women need to take tamoxifen for 5 years to prevent 1 case of invasive breast cancer in 10 years. Because of the treatment toxicities and limited benefit of tamoxifen or AI treatment after LRT, the use of these drugs remains low for preventing breast cancer recurrence. In addition, no overall survival benefit has been shown Original Article 16 conducted a study of 206,255 DCIS patients diagnosed from 2005 to 2012 in the National Cancer Data Base, and they found the adjuvant endocrine therapy initiation rate to be 46.4% among patients with ER-positive tumors. This rate is similar to our finding of 45.2%. The low rate of use may be attributable to adverse events and the excellent prognosis for DCIS patients.
In our study, women with mastectomy had a lower initiation rate than LRT women. These finding are not surprising: women who have been treated with mastectomy have a lower risk of developing new breast cancer because only 1 breast remains at risk. In this situation, the benefit of chemoprevention is smaller, and the risk/benefit ratio may not always favor treatment.
We found significantly higher use of tamoxifen or AIs among Hispanics than non-Hispanic whites; this result is consistent with previous findings. 9 A study evaluating hormone therapy among DCIS patients and based on 6 Kaiser Permanente regions from 2001 to 2011 found that Hispanic women were more likely than white women to receive hormone treatment (odds ratio, 1.20; 95% confidence interval, 1.02-1.40). 17 Our findings, which were generated from a large sample size from diverse US regions, confirm that race/ethnicity is a predictor of hormone therapy use. To our knowledge, this is the first population-based study to evaluate adherence to tamoxifen or AIs for ERpositive DCIS over 5 years among older women. Our adherence rate of 30% was much lower than that of the NSABP B35 trial (64%) and the IBIS-II DCIS trial (67%) with P values < .0001. 6, 7 The higher rates reported from the clinical trials are likely attributable to a highly select and motivated cohort of patients and detailed followup protocols. In contrast, our study is population-based with no follow-up protocol, and the patients were much older than those in the clinical trials. These differences speak to the importance of studying adherence in nationally representative, relatively unselected patient populations rather than relying on data from clinical trials.
Despite our important findings, our study has limitations. Because the median follow-up of our study was 34 months, the estimated adherence rates for the fourth and fifth years were less precise than the rates for the first 3 years. Also, information about treatment decision making and the extent to which it was influenced by patients or by health care providers was not available. However, a major strength of our study is that it is population-based and reflects tamoxifen or AI use among female Medicare beneficiaries who had Medicare Part D coverage. Our study provides useful information on treatment patterns for ER-positive DCIS patients and factors associated with use among older women. Interestingly, our finding that 23.9% of elderly patients underwent mastectomy indicates a decreasing trend of mastectomy among older DCIS patients.
Overall, the initiation of tamoxifen or AIs among older women with ER-positive DCIS was 45.2%, and the 5-year adherence rate was 30%. This low rate should lead to further studies to evaluate the reasons for the low uptake and adherence. The NSABP B24 clinical trial reported that tamoxifen treatment reduces subsequent breast cancer for ER-positive DCIS patients with a median follow-up time of 14.5 years. 18 Because the median follow-up time was only approximately 3 years for our study, we were not able to evaluate the breast cancer recurrence rate. In the future, when more years of Medicare Part D data are available, we will evaluate whether tamoxifen or AI use would reduce breast cancer events in population-based studies. Lastly, our study highlights the need to identify biomarkers that can identify patients at high risk for invasive recurrence to maximize the preventive effect and eliminate unnecessary harm in women with a low risk of breast cancer recurrence. Original Article
